Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting

Eyenovia announced that Drs. Siddarth Rathi and April Jasper will present the latest analyses and updates from the company’s clinical studies at the American Academy of Optometry Academy 2020 At Home Conference.

On Wednesday, October 7, April Jasper, OD, medical monitor for the company’s CHAPERONE study and member of the Eyenovia Scientific Advisory Board, will provide pre-recorded updates on the CHAPERONE (evaluation of low-dose atropine for the reduction of pediatric myopia progression) and the VISION (evaluation of low-dose pilocarpine for improvement in near vision) clinical trials. Dr. Jasper will also provide an update on the company’s upcoming MydCombi (low-dose tropicamide and phenylephrine fixed combination for pupil dilation) NDA filing with the FDA.

On Thursday, October 8 at 6 pm EDT, Siddarth Rathi, MD, of The Eye Institute of West Florida and medical monitor for the MIST 1 and MIST 2 studies, will present additional analyses of data from the MIST 1 and MIST 2 studies of Eyenovia’s proprietary first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Clinical results will cover Pupil Dilation Speed with MAP Fixed Combination (FC) Tropicamide 1% Phenylephrine 2.5% (TR-PH)-Ophthalmic Solution.

Presenter 1: April Jasper, OD, medical monitor for the Eyenovia’s CHAPERONE study and member of the Eyenovia Scientific Advisory Board

• Date: Wednesday, Oct. 7
• Time: Prerecorded for meeting opening
• Location: American Academy of Optometry Academy 2020 At Home Con
• Content:
  • Updates to CHAPERONE (evaluation of low-dose atropine for the reduction of pediatric myopia progression) and the VISION (evaluation of low-dose pilocarpine for improvement in near vision) clinical trials
  • Update on the company’s upcoming MydCombi (low-dose tropicamide and phenylephrine fixed combination for pupil dilation) NDA filing with the U.S. Food and Drug Administration (FDA)

Presenter 2: Siddarth Rathi, MD, of The Eye Institute of West Florida and medical monitor for the MIST 1 and MIST 2 studies

• Date: Thursday, Oct. 8
• Time: 6 pm EDT
• Location: American Academy of Optometry Academy 2020 At Home Con
• Content:
  • Additional analyses of data from the MIST 1 and MIST 2 studies of Eyenovia’s proprietary first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation)